What is Audeo Oncology Scaled Net Operating Assets?
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Audeo Oncology's operating assets for the quarter that ended in Sep. 2012 was $3.28 Mil. Audeo Oncology's operating liabilities for the quarter that ended in Sep. 2012 was $5.74 Mil. Audeo Oncology's Total Assets for the quarter that ended in Jun. 2012 was $9.71 Mil. Therefore, Audeo Oncology's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2012 was -0.25.
Audeo Oncology Scaled Net Operating Assets Historical Data
The historical data trend for Audeo Oncology's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Audeo Oncology Scaled Net Operating Assets Chart
|
Audeo Oncology Annual Data
|
|
Trend |
Jun10 |
Jun11 |
Jun12 |
| Scaled Net Operating Assets |
|
-98.87 |
-193.91 |
-0.68 |
|
Audeo Oncology Quarterly Data
|
|
Jun11 |
Mar12 |
Jun12 |
Sep12 |
| Scaled Net Operating Assets |
-24.45 |
-29.33 |
-0.41 |
-0.25 |
Competitive Comparison of Audeo Oncology's Scaled Net Operating Assets
For the Drug Manufacturers - General subindustry, Audeo Oncology's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Audeo Oncology's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Audeo Oncology's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Audeo Oncology's Scaled Net Operating Assets falls into.
Audeo Oncology Scaled Net Operating Assets Calculation
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Audeo Oncology's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Jun. 2012 is calculated as
| Scaled Net Operating Assets (SNOA) | | (A: Jun. 2012 ) |
| = | (Operating Assets (A: Jun. 2012 ) | - | Operating Liabilities (A: Jun. 2012 )) | / | Total Assets (A: Jun. 2011 ) |
| = | (2.056 | - | 2.679) | / | 0.912 |
| = | -0.68 |
where
Audeo Oncology's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2012 is calculated as
| Scaled Net Operating Assets (SNOA) | | (Q: Sep. 2012 ) |
| = | (Operating Assets (Q: Sep. 2012 ) | - | Operating Liabilities (Q: Sep. 2012 )) | / | Total Assets (Q: Jun. 2012 ) |
| = | (3.281 | - | 5.744) | / | 9.712 |
| = | -0.25 |
where
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Audeo Oncology (Audeo Oncology) Business Description
Traded in Other Exchanges
N/A
Address
Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.
Audeo Oncology (Audeo Oncology) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DELISTED:AURX has been successfully added to your